Merck to Acquire Terns Pharmaceuticals for $6.7 Billion to Bolster Cancer Drug Pipeline
Merck has announced a $6.7 billion agreement to acquire Terns Pharmaceuticals, a company focused on developing novel cancer therapies, including an oral treatment for leukemia.
Merck announced on Tuesday that it has entered into a definitive agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion. The deal aims to enhance Merck's oncology portfolio by integrating Terns Pharmaceuticals' pipeline of cancer treatments.
Terns Pharmaceuticals is known for its work on novel therapeutics, including a potential oral therapy for leukemia. This acquisition signals Merck's strategic intent to expand its offerings in the competitive landscape of cancer drug development. The transaction is expected to close in the second half of 2024, subject to customary closing conditions, including regulatory approvals.
Key Takeaways
- Merck is acquiring Terns Pharmaceuticals for $6.7 billion.
- The deal includes Terns Pharmaceuticals' pipeline, notably an oral leukemia treatment.
- The acquisition is expected to close in the second half of 2024.
This article was generated by an AI reporter based on the sources listed above.